Owen Mumford

Owen Mumford is a medical device manufacturer that develops products for its own brand and custom device solutions for pharmaceutical and diagnostic companies. Owen Mumford provides research, design and manufacturing capabilities for device production.

Headquarters
Owen Mumford Ltd
Brook Hill, Woodstock
Oxfordshire
OX20 1TU
United Kingdom

Phone / Contact

T: +44 1993 812 021
F: +44 1993 813 466
E: [email protected]

Connect

Owen Mumford is a medical device manufacturer that develops products for its own brand and custom device solutions for pharmaceutical and diagnostic companies. Owen Mumford provides research, design and manufacturing capabilities for device production.

Articles by Owen Mumford

Olivia Houselander

THE CHALLENGES OF DEVELOPING DRUG DELIVERY DEVICES FOR THE JAPANESE MARKET

Olivia Houselander outlines some of the challenges of developing drug delivery devices for the Japanese market and shares details of Owen Mumford’s latest two products to gain approval in Japan.

DESIGN FOR SUSTAINABILITY – THE CONSIDERATIONS BROUGHT TO LIFE

Oli Gould explores the use of lifecycle assessment in product design for sustainability to impact the environment positively.

PRACTICAL PATHWAYS TO SUSTAINABILITY

Alex Fong and Olivia Houselander discuss the importance of sustainability in the healthcare sector and the challenges that must be overcome to achieve it in a meaningful and lasting way.

CONQUERING THE CHALLENGES OF CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT

Michael Earl discusses the factors that need to be taken into account for successful connected drug delivery device development.

Isobel Filipova

SUSTAINABILITY IN DRUG DELIVERY – STATE OF PLAY IN 2023

Isobel Filipova of Owen Mumford explains where the healthcare industry stands on current environmental objectives, identifies obstacles to achieving sustainability in drug delivery and looks at how the sector can make progress to meet its objectives.

DEVICE INTERCHANGEABILITY STUDY OF THREE-STEP AND TWO-STEP AUTOINJECTORS

Alex Fong discusses the results of a study assessing patients’ ability to switch from a three-step autoinjector to a two-step device.

HARNESSING HUMAN FACTORS IN CONNECTED DEVICE DEVELOPMENT

Finola Austin looks at the role human factors testing plays in the development of connected drug delivery devices.

THE OPERATIONS PERSPECTIVE: BEST PRACTICES FROM 70 YEARS IN INJECTION DEVICE MANUFACTURING

John Swift looks at how the company has evolved over 70 years, introduces its latest disposable autoinjector, Aidaptus, and considers how it plans to actively reduce risk in its supply chain.

AREAS TO WATCH IN CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT

Michael Earl identifies areas of development in the field of connected drug delivery devices, providing an insight into what can be expected in the coming years. He draws on Owen Mumford’s own research, as well as discussions with industry experts and counterparts.

PREFILLED SYRINGES

COMPANY SHOWCASE: Owen Mumford Pharmaceutical Services

Owen Mumford Pharmaceutical Services specialises in the design, development and manufacture of injectable drug delivery systems for the pharma, biotech and generics industries. Its trusted devices are used daily in the delivery of various medications for a multitude of conditions across the globe.

SUPPORTING PATIENTS ON THE ROAD TO SELF-CARE

Michael Earl discusses the importance of transitioning current healthcare models to embrace patient self-management and how advanced drug delivery device technologies, such as connectivity, can ease this burden on overstretched healthcare services.

A CHECKLIST FOR AUTOINJECTOR DESIGN

Michael Earl outlines the five key questions autoinjector designers typically ask during the development process and the choices available for tailoring autoinjector products.

INTERVIEW: STEVEN KAUFMAN, STEVANATO GROUP, & MICHAEL EARL, OWEN MUMFORD

In this exclusive interview, Steven Kaufman of Stevanato Group, and Michael Earl of Owen Mumford, talked with us about their companies' recent major agreement for the manufacturing and provision of prefillable syringes for the advanced two-step, single-use autoinjector, Aidaptus^®.

SO FAR SO GOOD: MAINTAINING THE MOMENTUM OF PROGRESS FOR SUSTAINABLE POLICIES

Michael Earl discusses the highlights of a review undertaken by Owen Mumford into how the pharmaceutical industry is faring on environmental, social and governance standards, noting that while the industry is performing above average overall, there remain some key areas for improvement.

Julie Cotterell

FORMULATION DEVELOPMENT AND DRUG DELIVERY: JOINED AT THE DEVICE

Julie Cotterell discusses the major factors at play driving the direction of innovation in the subcutaneous drug delivery space, with a particular emphasis on the push towards patient self-administration.

AIDAPTUS^®: OWEN MUMFORD INTRODUCES ITS NEXT-GENERATION PLATFORM AUTOINJECTOR

Michael Earl introduces the next-generation Aidaptus^® autoinjector, explaining how this latest platform device from Owen Mumford can contribute to a faster speed-to-market, increased flexibility during drug development and improved patient outcomes.

Mr Denis Marteau

ARE VIRTUAL EVENTS A SUITABLE REPLACEMENT FOR FACE-TO-FACE EQUIVALENTS POST-PANDEMIC?

Denis Marteau looks at the future of virtual industry events and conferences in a post-pandemic future.

INDUSTRIALISATION

PUTTING POST-PANDEMIC SUPPLY CHAINS TO THE TEST

John Swift discusses the need for medtech companies to undertake a reappraisal of their supply chains in light of covid-19, taking into consideration how the pandemic has exposed vulnerabilities that have previously gone unnoticed or ignored.

Miranda Newbery

HOW OWEN MUMFORD CARRIED OUT USABILITY TESTING UNDER COVID-19 RESTRICTIONS

Miranda Newbery describes working with Owen Mumford Pharmaceutical Services on usability testing for a platform autoinjector under covid-19 restrictions.

ROOM FOR INNOVATION?

Darren Mansell examines US FDA guidance on biosimilar interchangeability and asks whether there is room for innovation.

PREFILLED SYRINGES

AN INCLUSIVE APPROACH TO THE DEVELOPMENT OF PLATFORM MEDICAL DEVICES

Finola Austin discusses the difficulties presented by designing a user testing programme for platform devices when the target patient population is as yet unknown, and presents the testing framework based on seven user groups that Owen Mumford uses to meet this challenge.

CONNECTED DRUG DELIVERY: ACHIEVING OPTIMAL BENEFITS THROUGH SMART COLLABORATION

George I’ons discusses the challenges developing connected devices presents to key market stakeholders when it comes to successful rollout and implementation. Additionally, he considers the perspectives of these market players, as well as the patients themselves, with respect to how connected drug delivery devices can help them to better achieve their desired outcomes.

PREFILLED SYRINGES

UNISAFE^® 2.25: SEAMLESSLY TRANSITIONING TO NEW-GENERATION BIOLOGICS

George I’ons discusses the benefits of subcutaneously administering new drug formulations, and the factors that manufacturers need to consider when designing delivery devices.

FROM DESIGN TO DISPOSAL: ACHIEVING SUSTAINABILITY IN MEDICAL DEVICES

George I’ons discusses the onus on the device design industry to move towards sustainable practices, including what this entails, how it might be achieved and what benefits sustainability may bring.

Top